NCT06451640已完成2 期
A Multicenter, Randomized, Ongoing Trial Evaluating the Long-term Safety and Efficacy of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.16 个研究点 分布在 1 个国家目标入组 59 人开始时间: 2024年7月4日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 59
- 试验地点
- 16
- 主要终点
- Treatment-related adverse event rate
研究概览
简要总结
This study aims to evaluate the efficacy and safety of TQC2731 injection in the treatment of chronic sinusitis with nasal polyps.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects sign informed consent before study, fully understand the purpose, procedures and possible adverse reactions of the study;
- •Male and female, ≥18 years old;
- •Participate in the clinical study of TQC2731 for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) (study number TQC2731-II-02) and meet the following criteria "a" or "b": a. Participants complete the prescribed treatment according to the protocol requirements and complete end of treatment (EOT) visits; b. The subject withdrew early due to poor compliance or other objective reasons other than TQC2731 related adverse events (AEs), and completed the early withdrawal visit according to the plan. After evaluation by the researcher and sponsor, the factors that led to the subject's early termination of the main study treatment have disappeared/no longer affect the subject's participation in this continuing study;
- •Subjects used steady dose of intranasal glucocorticoids (INCS) over 4 weeks before screening (subjects willing to use Mometasone Furoate Aqueous Nasal Spray (MFNS) while studying);
- •Subjects agree from sign informed consent to last administration over 6 mouth without Family planning，and take effective non-pharmaceutical contraception.
排除标准
- •In the main study (TQC2731-II-02), SAE related to TQC2731 occurred, or TQC2731 treatment was terminated due to AE related to TQC
- •After discussion between the investigator and the sponsor, it was determined that the subject was not suitable to continue receiving TQC2731 treatment;
- •The subjects had poor compliance in the main study and were deemed unable to complete this continuing study by the researchers;
- •During the main study (TQC2731-II-02), any serious progression or poorly controlled comorbidities were found (such as asthma exacerbation requiring adjustment of background medication), and the main investigator determined that the subject was not suitable to participate in the trial;
- •Presence of conditions/concomitant diseases that affect the evaluation of efficacy, e.g.
- •Posterior nostril polyps;
- •Imaging suspected or confirmed fungal sinusitis;
- •Nasal polyp score(NPS) cannot be evaluated due to nasal surgery to alter the structure of the lateral nasal wall;
- •Subjects with nasal malignancies and benign tumors (papilloma, blood furuncle, etc.).
- •Any type of active malignancy or a history of malignancy (Patient with basal cell carcinoma, skin localized squamous cell carcinoma or carcinoma in situ of cervix, if curative treatment was completed for more than 12 months prior to visit 1 can join the study; Other malignant tumors can join the study if patients had completed curative therapy for at least 5 years prior to visit 1);
- •Active autoimmune disease;
- •Known or suspected history of immunosuppression, immune dysfunction, or immune dysfunction, including but not limited to invasive opportunistic infections, even if the infection has subsided;
- •Uncontrolled epistaxis occurred within 2 months before screening;
- •Infection requiring treatment with systemic antibacterial, antiviral, antifungal, antiparasitic, or antiparasitic agents occurred within 14 days before screening;
- •Helminth parasite infection was diagnosed within 24 weeks prior to screening and had not received or failed to respond to standard treatment;
- •Leukotriene antagonists/modulators were used while screening(using a stable dose of leukotriene modulator for ≥30 days before screening was accepted);
- •Regular use of decongestants (topical or systemic) before screening, short-term use for endoscopy excepted;
- •Patients who received any of the following treatments before screening:
- •Immunosuppressive therapy had been administered within the previous 8 weeks or five half-lives (whichever was longer), (including but not limited to cyclophosphamide, cyclosporine, interferon-γ, azathioprine, methotrexate, mycophenolate mofetil and tacrolimus, etc.);
- •Monoclonal antibody therapy had been administered within the previous 8 weeks or five half-lives (whichever was longer), (Including but not limited to: benralizumab, mepolizumab, omalizumab, resveratrol, dupilumab, etc.);
- •Systemic glucocorticoids were used during the first 28 days;
- •Glucocorticoid-eluting nasal stents were used during the first 6 mouths;
- •Immune globulin or blood products therapy were used during the first 28 days; 6）Live attenuated vaccine was administered for the first 28 days or during the planned study period; 7）Received allergen specific immunotherapy 6 mouth before screening(if being treated at a stable dose and not expected to change during study,3 mouth before screening and 1 mouth before visit 1 were accepted); 8）Join any other study within 3 mouths.
- •Patients with concomitant asthma begin inhaled corticosteroid therapy within the first 4 weeks of the screening period (For patients who have been assessed to maintain a stable dose for at least 4 weeks prior to screening and whose dose has been maintained throughout the entire study period, inhaled corticosteroids can be administered at a dose of ≤ 1000μ Fluticasone propionate or equivalent doses of other inhaled corticosteroids.);
- •Any infectious disease screening indicator that meets the following criteria during screening:
- •Active tuberculosis infection during screening;
- •Hepatitis B virus surface antigen (HBsAg) positive, or hepatitis B core antibody (HBcAb) positive and hepatitis B virus (HBV) DNA positive;
- •Anti-hepatitis C virus (Anti-HCV) positive and Hepatitis C virus ribonucleic acid (HCV-RNA) positive;
- •Positive Treponema pallidum antibody (Anti TP) (if the Treponema pallidum serological test is positive, further non treponema pallidum serological tests will be conducted, the latter being negative and judged by the researcher as a patient who has previously been infected with syphilis but has been cured and meets the inclusion criteria);
- •Positive for human immunodeficiency virus antibodies (Anti HIV);
- •Abnormal laboratory test results:
- •Aspartate aminotransferase (AST)>2.5 x upper limit of normal value (ULN);
- •Alanine aminotransferase (ALT)>2.5 x upper limit of normal value (ULN);
- •Creatinine>1.5 x ULN.
- •Pregnant or lactating women;
- •A history of or allergic reaction to Mometasone furoate nasal spray (Nasonex ®) or any component of TQC2731 injection;
- •A history of systemic allergy to any biologic drug(except local injection site reactions);
- •The subjects had poor compliance and were judged unable to complete the study;
- •Any clinically significant abnormal findings, including physical examination, vital signs, 12-lead electrocardiogram, blood biochemistry, blood routine or urine routine, and the researcher's judgment that participating in the trial may put the patient at risk, or may affect the study results or hinder the patient's ability to complete the entire study process.
研究组 & 干预措施
210mg of TQC2731 injection
Experimental
210mg of TQC2731 injection combined with Mometasone Furoate Aqueous Nasal Spray, 28days as a treatment cycle.
干预措施: 210mg of TQC2731 injection (Drug)
420mg of TQC2731 injection
Experimental
420mg of TQC2731 injection combined with Mometasone Furoate Aqueous Nasal Spray, 28days as a treatment cycle.
干预措施: 420mg of TQC2731 injection (Drug)
结局指标
主要结局
Treatment-related adverse event rate
时间窗: Up to thirty six weeks
The frequency of treatment-related adverse events (TEAEs) occurring during treatment at each evaluation time point.
次要结局
- Treatment-related serious adverse events rate(Up to thirty six weeks)
- Immunogenicity-anti-drug antibody(1 hour on day 1 before administration, day 197, day 253 during withdrawal)
- Nasal congestion score (NCS)(Baseline up to thirty six weeks)
- Abnormal laboratory test indicators(Up to thirty six weeks)
- Nasal Polyp Score (NPS)(Baseline up to thirty six weeks)
- Total symptom score (TSS)(Baseline up to thirty six weeks)
- Anosmia score(Baseline up to thirty six weeks)
- Visual analogue scale (VAS) for sinusitis(Baseline up to thirty six weeks)
- Lund Mackay (LMK) score(Baseline up to twenty eight weeks)
- Immunogenicity-neutralizing antibody(1 hour on day 1 before administration, day 197, day 253 during withdrawal)
研究者
研究点 (16)
Loading locations...
相似试验
进行中（未招募）
2 期
A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary DiseaseNCT06707883Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.258
已完成
2 期
A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.SinusitisNCT06089278Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.160
进行中（未招募）
早期 1 期
Study of CT071 Injection in RRMM or PPCLPrimary Plasma Cell LeukemiaMultiple MyelomaNCT05838131Shanghai Changzheng Hospital20
已完成
2 期
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT06527144Chia Tai Tianqing Pharmaceutical Group Co., Ltd.240
已完成
3 期
TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase InhibitorsHIV-1HIV InfectionsNCT00543725Tibotec Pharmaceuticals, Ireland680